Markers for targeted therapy and prognosis in high-grade serous ovarian cancer

An ovarian cancer, liquid technology, applied in the field of biomedicine, can solve the problems of prognosis and drug resistance that have not been reported in the literature

Active Publication Date: 2020-11-03
SHANDONG UNIV QILU HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, the relationship between PRC1 and the prognosis and drug resistance of high-grade serous ovary has not been reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Markers for targeted therapy and prognosis in high-grade serous ovarian cancer
  • Markers for targeted therapy and prognosis in high-grade serous ovarian cancer
  • Markers for targeted therapy and prognosis in high-grade serous ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] 1. Experimental method:

[0035] We collected archival wax blocks of surgical specimens from 48 patients with fimbria and 210 patients with high-grade serous ovarian cancer from 2007-2016. Using a semi-automatic tissue chip punching machine to make 5 TMA tissue chips to ensure large samples, high throughput and standardization of immunohistochemistry. Each block contains fimbria and high-grade serous ovarian carcinoma.

[0036]Tissue Microarray (TMA) technology is a microarray tissue sheet made by neatly arranging dozens to hundreds or even more tissue samples on a glass slide. Through immunohistochemistry, in situ hybridization, etc., high-throughput acquisition of genomics and proteomics expression information based on morphology has been achieved on tissue sections. Tissue chip technology has been widely used in tumor research to study the changes of genes and proteins in different development stages of tumors, the evaluation of prognosis, the evaluation of molecul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of PRC1 (protein regulating cytokinesis 1) as a marker for prognosis and / or targeted therapy of HGSOC (high-grade serous ovarian carcinoma) and an application ofa reagent for detecting PRC1 in preparation a kit for prognosis and / or targeted therapy of HGSOC. Prognosis, recurrence time and sensitivity of platinum-containing chemotherapy of HGSOC are judged byPRC1 as a marker with an immunohistochemical method. PRC1 has high expression in HGSOC, especially remarkable in non-BRCA-induced mutant ovarian cancer, but has low expression in normal fimbriae of uterine tube. The characteristic can be used for predicting the overall lifetime and 3-5-year survival rate of patients. PRC1, as the marker for prognosis and / or targeted therapy of HGSOC, has broad application prospect and huge potential social benefits.

Description

technical field [0001] The invention relates to the field of biomedical technology, in particular to a molecular marker that can be used for prognosis judgment and targeted therapy of high-grade serous ovarian cancer, and a reagent, kit or chip for detecting the marker. Background technique [0002] Ovarian cancer is a common malignant tumor in gynecology, and its case fatality rate ranks first among gynecological malignant tumors. It is the biggest challenge facing obstetrics and gynecology. Although tumor cytoreductive surgery and platinum-taxane combination chemotherapy have improved the 5-year survival rate of patients, there has been no substantial progress in the clinical diagnosis and treatment of ovarian cancer in the past half a century, mainly due to the lack of long-lasting therapeutic options, and The fundamental reason lies in the unclear understanding of the molecular mechanisms of the occurrence and development of ovarian cancer and multi-drug resistance. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68
CPCG01N33/68
Inventor 孔北华步华磊李英伟靳成娟苑存忠陈晶莹张智伟
Owner SHANDONG UNIV QILU HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products